UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~November~~December 96, 2022

Commission File Number: 001-36686

(Commission file number)

Forward Pharma A/S

~~(Translation~~Østergade of24A, ~~registrant’s~~1st ~~name~~Floor1100 ~~into~~Copenhagen ~~English)~~K, Denmark

Østergade 24A, 1st Floor

1100 Copenhagen K, Denmark

(Address of principal executive office)

________________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by by Regulation S-T Rule 101(b)(1): ~~Yes~~ ☐  ~~No ☒~~

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by by Regulation S-T Rule 101(b)(7): ~~Yes~~ ☐  ~~No ☒~~

~~Indicate~~Item by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 19341. ~~Yes~~ Other ~~☐  No ☒~~Items

IfOn ~~“Yes”~~December is6, ~~marked~~2022, ~~indicate~~Forward ~~below~~Pharma A/S issued a press release regarding the ~~file~~decision ~~number~~of ~~assigned~~the toEnlarged Board of Appeal of the ~~registrant~~European Patent Office in ~~connection~~ ~~with~~the ~~Rule~~EP2801355 ~~12g3-2(b):~~petition ~~N/A~~for review, a copy of which is attached hereto as Exhibit 99.1.

~~Item~~EXHIBIT ~~1. Other Items~~INDEX

On November 21, 2022, Forward Pharma A/S (the “Company”) made available on its website Amended and Restated Articles of Association, dated November 9, 2022, which were filed with the Danish Business Authority on November 14, 2022. The Amended and Restated Articles of Association reflect changes due to the exercise of warrants.

Exhibit No.		Description

99.1		Press Release dated December 6, 2022

~~The Company has filed as an exhibit to this Form 6-K the Amended and Restated Articles of Association, dated November 9, 2022.~~SIGNATURES

~~SIGNATURE~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	FORWARD PHARMA A/S


Date: December 6, 2022	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

Date: November 21, 2022		Forward Pharma A/S
	By:	/s/ Claus Bo Svendsen
		Name: Claus Bo Svendsen
		Title: Chief Executive Officer

EXHIBIT INDEX

99.1 Amended and Restated Articles of Association, dated November 9, 2022.

Filing Compare · Forward Pharma A/S